July 2009 Volume 27 Number 7, pp 579 - 674
Visit Nature Biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=53&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=32&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=40&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=5&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
PepChip kinome profiling introduction offer
http://links.ealert.nature.com/ctt?kn=45&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Have you ever wanted to see a panoramic view of kinase activities in
cells and tissues? Now you can with kinome profiling.
The value of PepChip Kinomics has been shown independently in over
22 high-level papers.
This is your chance to see what kinome profiling can do for you.
Check out our special offer now.
http://links.ealert.nature.com/ctt?kn=45&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
=====================================================================
=========================== ADVERTISEMENT ===========================
FREE ARTICLE
***A new approach to hypercholesterolemia****
http://links.ealert.nature.com/ctt?kn=84&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Researchers at Amgen Inc report that an antibody against PCSK9, a genetically validated target for hypercholesterolemia, can lower cholesterol in mice and nonhuman primates. The findings bolster the case for using mAbs to soak up PCSK9 in the extracellular space as a therapeutic strategy for hypercholesterolemia, and provide competition to gene silencing strategies that block production of the protease and are in development by Alnylam Pharmaceuticals Inc and Isis Pharmaceuticals Inc.
****************************************************************
Access 20 FREE ARTICLES at SciBX Cover Story Archive
http://links.ealert.nature.com/ctt?kn=130&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
Credit where credit is overdue p579
A universal tagging system that links data sets with the author(s) that generated them is essential to promote data sharing within the proteomics and other research communities.
doi:10.1038/nbt0709-579
http://links.ealert.nature.com/ctt?kn=101&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
----------------------
NEWS
----------------------
Sanofi Aventis grooms its ranks for biotech partnering pp581 - 582
Nuala Moran
doi:10.1038/nbt0709-581
http://links.ealert.nature.com/ctt?kn=15&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Governments fiddle while biotech burns pp583 - 585
Peter Mitchell
doi:10.1038/nbt0709-583
http://links.ealert.nature.com/ctt?kn=21&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Lilly's free web screening p584
Jim Kling
doi:10.1038/nbt0709-584
http://links.ealert.nature.com/ctt?kn=28&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
GE animal SBIR break p585
Jeffrey L Fox
doi:10.1038/nbt0709-585a
http://links.ealert.nature.com/ctt?kn=58&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Chavez own brand p585
Victor Bethencourt
doi:10.1038/nbt0709-585b
http://links.ealert.nature.com/ctt?kn=87&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Ontario's $100 million draw p586
Stephen Strauss
doi:10.1038/nbt0709-586a
http://links.ealert.nature.com/ctt?kn=76&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Algae trailblazer shuts p586
Emily Waltz
doi:10.1038/nbt0709-586b
http://links.ealert.nature.com/ctt?kn=123&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Diagnostics firms face new patent claim worries pp586 - 587
Malorye Allison
doi:10.1038/nbt0709-586c
http://links.ealert.nature.com/ctt?kn=119&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Budget winners p587
Jeffrey L Fox
doi:10.1038/nbt0709-587
http://links.ealert.nature.com/ctt?kn=122&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Report claims no yield advantage for Bt crops pp588 - 589
Cormac Sheridan
doi:10.1038/nbt0709-588
http://links.ealert.nature.com/ctt?kn=72&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
PROFILE
iZumi's plans to capitalize on iPS cells pp590 - 591
Monya Baker
doi:10.1038/nbt0709-590
http://links.ealert.nature.com/ctt?kn=148&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
NEWS FEATURE
Up in arms pp592 - 594
Several European countries continue to defy EU law and ban genetically modified maize. Will the stalemate ever be resolved? Gunjan Sinha investigates.
Gunjan Sinha
doi:10.1038/nbt0709-592
http://links.ealert.nature.com/ctt?kn=30&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Six secrets to success - how to build a sustainable biotech business
What are the core elements of a successful biotech?
Francesco De Rubertis, Roman Fleck and Werner Lanthaler
doi:10.1038/bioe.2009.5
http://links.ealert.nature.com/ctt?kn=41&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
PRIDE Converter: making proteomics data-sharing easy pp598 - 599
Harald Barsnes, Juan Antonio Vizcaino, Ingvar Eidhammer and Lennart Martens
doi:10.1038/nbt0709-598
http://links.ealert.nature.com/ctt?kn=23&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
NCBI Peptidome: a new public repository for mass spectrometry peptide identifications pp600 - 601
Douglas J Slotta, Tanya Barrett and Ron Edgar
doi:10.1038/nbt0709-600
http://links.ealert.nature.com/ctt?kn=81&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
More eyeballs on AERS pp601 - 602
Leslie A Pratt and Paul N Danese
doi:10.1038/nbt0709-601
http://links.ealert.nature.com/ctt?kn=134&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Lessons in biopolitics pp602 - 604
Shane Morris
doi:10.1038/nbt0709-602
http://links.ealert.nature.com/ctt?kn=150&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Metabolic reconfiguration precedes transcriptional regulation in the antioxidant response pp604 - 605
Markus Ralser et al.
doi:10.1038/nbt0709-604
http://links.ealert.nature.com/ctt?kn=33&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
COMMENTARY
Developing safe therapies from human pluripotent stem cells pp606 - 613
Translation of human pluripotent stem cells into cell therapies will require the development of standardized tests for product consistency, stability, tumorigenicity, toxicity and immunogenicity.
Melissa K Carpenter, Joyce Frey-Vasconcells and Mahendra S Rao
doi:10.1038/nbt0709-606
http://links.ealert.nature.com/ctt?kn=95&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
----------------------
FEATURES
----------------------
PATENTS
Dynamics of global disclosure through patent and journal publications for biopharmaceutical products pp614 - 618
Examining the relationships between invention disclosure type in industry and academia and geographical disclosure trends, using plant-made pharmaceuticals as a single-sector model for the biopharmaceutical industry.
Harry Thangaraj, Craig J van Dolleweerd, Edward G McGowan and Julian K-C Ma
doi:10.1038/nbt0709-614
http://links.ealert.nature.com/ctt?kn=70&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Recent patent applications in stem cells p619
doi:10.1038/nbt0709-619
http://links.ealert.nature.com/ctt?kn=83&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Minicells overcome tumor drug-resistance pp620 - 621
Bacterially derived minicells loaded with siRNA reverse drug resistance in tumor xenografts.
Emmanouil D Karagiannis and Daniel G Anderson
doi:10.1038/nbt0709-620
http://links.ealert.nature.com/ctt?kn=93&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Biomarker validation by targeted mass spectrometry pp622 - 623
A multilaboratory study demonstrates the potential for establishing quantitative targeted proteomic assays for moderately to highly abundant plasma proteins.
Martin McIntosh and Matthew Fitzgibbon
doi:10.1038/nbt0709-622
http://links.ealert.nature.com/ctt?kn=139&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
The importance of being red pp624 - 625
A near-infrared fluorescent protein opens a window into the mammalian body.
Bradley W Rice and Christopher H Contag
doi:10.1038/nbt0709-624
http://links.ealert.nature.com/ctt?kn=36&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Research highlights p626
doi:10.1038/nbt0709-626
http://links.ealert.nature.com/ctt?kn=42&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
----------------------
COMPUTATIONAL BIOLOGY
----------------------
PERSPECTIVE
Fifteen years of microbial genomics: meeting the challenges and fulfilling the dream pp627 - 632
Now that ~1,000 microbial genomes have been sequenced, Nikos Kyrpides reflects on the past decade of microbial genomics and extrapolates forward to propose solutions to meeting challenges in the field.
Nikos C Kyrpides
doi:10.1038/nbt.1552
http://links.ealert.nature.com/ctt?kn=86&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
----------------------
RESEARCH
----------------------
ANALYSIS
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma pp633 - 641
Terri A Addona et al.
doi:10.1038/nbt.1546
Abstract: http://links.ealert.nature.com/ctt?kn=6&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=117&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
ARTICLES
Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug pp643 - 651
Drug resistance remains a major hurdle to effective cancer chemotherapy. MacDiarmid et al. show that bacterially derived minicells packaged with siRNAs reverse tumor drug resistance and that subsequent treatment with minicells loaded with cytotoxic drugs causes tumor stabilization or regression.
Jennifer A MacDiarmid et al.
doi:10.1038/nbt.1547
Abstract: http://links.ealert.nature.com/ctt?kn=10&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=146&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Quantification of the yeast transcriptome by single-molecule sequencing pp652 - 658
Lipson et al. profile the yeast transcriptome using single-molecule sequencing. This approach avoids the inherent biases of the digestion, ligation and amplification steps in alternative methods based on microarrays or other sequencing technologies.
Doron Lipson et al.
doi:10.1038/nbt.1551
Abstract: http://links.ealert.nature.com/ctt?kn=63&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=90&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Synergistic drug combinations tend to improve therapeutically relevant selectivity pp659 - 666
Although combinations of drugs are often more potent than single agents, they are also believed to induce worse side effects. By screening >94,000 drug pairs in vitro, Lehar et al. show that synergistic combinations tend to be more selective than single drugs and are therefore unlikely to cause synergistic side effects.
Joseph Lehar et al.
doi:10.1038/nbt.1549
Abstract: http://links.ealert.nature.com/ctt?kn=88&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=125&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
LETTER
Rapid and systematic analysis of the RNA recognition specificities of RNA-binding proteins pp667 - 670
Until now, determining the sequences recognized by an RNA-binding protein has been time and labor intensive. Ray et al. use a custom pool of >210,000 oligos that encode linear and stem-loop RNAs to rapidly determine the sequences bound by nine RNA-binding proteins.
Debashish Ray et al.
doi:10.1038/nbt.1550
Abstract: http://links.ealert.nature.com/ctt?kn=107&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=60&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
----------------------
CORRIGENDUM
----------------------
Corrigendum: Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs p671
Aly A Khan et al.
doi:10.1038/nbt0709-671a
http://links.ealert.nature.com/ctt?kn=17&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
----------------------
ERRATA
----------------------
Erratum: Venture capital shifts strategies, startups suffer p671
Peter Mitchell
doi:10.1038/nbt0709-671b
http://links.ealert.nature.com/ctt?kn=11&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Erratum: New relief for gout p671
Jill U Adams
doi:10.1038/nbt0709-671c
http://links.ealert.nature.com/ctt?kn=113&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Erratum: Biotech hirings and firings p671
Michael Francisco
doi:10.1038/nbt0709-671d
http://links.ealert.nature.com/ctt?kn=144&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Erratum: Wyeth preemption case ruling sparks labeling confusion p671
Malorye Allison
doi:10.1038/nbt0709-671e
http://links.ealert.nature.com/ctt?kn=46&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
Erratum: Academia and the company coin p671
Jim Kling
doi:10.1038/nbt0709-671f
http://links.ealert.nature.com/ctt?kn=56&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
----------------------
CAREERS AND RECRUITMENT
----------------------
CAREERS AND RECRUITMENT
Small-cap biotechs in dire straits pp672 - 673
Michael Francisco
doi:10.1038/nbt0709-672
http://links.ealert.nature.com/ctt?kn=89&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
PEOPLE
People p674
doi:10.1038/nbt0709-674
http://links.ealert.nature.com/ctt?kn=12&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
nature.com open innovation pavilion
Seeking Solvers
nature.com has teamed up with InnoCentive to offer its readers the opportunity to participate in research and development Challenges. As a Solver, you can apply your expertise to important problems, stretch your creative boundaries, and win cash awards.
Visit the nature.com open innovation pavilion and you can become the next great Solver.
http://links.ealert.nature.com/ctt?kn=18&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=14&m=33565232&r=MTc3MTg2NzE2NgS2&b=2&j=NTI4ODkzMjcS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
